Submaximal dose of trandolapril in the COOPERATE trial?  by Jacobsen, Peter & Parving, Hans-Henrik
Letters to the Editor 1921
100 mg a day for 68 months. The patients, a mother and
son, had a heterozygous 481T→C mutation in the uromo-
dulin gene, causing a C126R amino acid change predicted
to disrupt the tertiary structure of Tamm-Horsfall glyco-
protein [3]. The mother, age 53, had a CrCl of 38 mL/
min, which decreased to 16 mL/min within one year. After
introduction of benzbromarone 100 mg her renal function
stabilized and her actual CrCl was 17 mL/min. The 32-
year-old son had a CrCl of 58 mL/min. His renal function
also remained stable under benzbromarone 100 mg, with
an actual CrCl of 60 mL/min. We think that a trial of
benzbromarone is justified in patients with FJHN. If benz-
bromarone proves to be effective this would also imply
that reduced FEUA is of pathogenetic importance. There
is nothing to be lost, but possibly much to win using benz-
bromarone in FJHN.
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Submaximal dose of
trandolapril in the
COOPERATE trial?
To the Editor: In the recent study published in Kidney
International by Jacobsen et al [1], the authors considered
the dose of angiotensin-converting enzyme inhibitor used
in the COOPERATE trial [2] to be submaximal. With
regard to this issue, however, we disagree with the authors.
Trandolapril at a dose of 3 mg is sufficient. First, the base-
line renal function of the enrollee was moderately re-
duced (mean serum creatinine level, 265 12.5 mmol/L).
In Japan, the recommended maximum dose of trandola-
pril is 2 mg, mainly for patients with uncomplicated es-
sential hypertension. Thus, pharmacies strongly request
us to reduce the dose in patients with renal dysfunction.
Second, during a run-in period, we had confirmed the
individual maximal anti-proteinuric efficacy of trandola-
pril using an up-titration scale from 0.5 to 6.0 mg. Of
301 patients, 240 showed dose-response reactions up to
3 mg. Above this dose, however, no additional anti-
proteinuric benefit was obtained. Third, the more a dose
was increased, the higher the tendency for side effects,
including hypotension, gastrointestinal symptoms, and
acute renal decline or low compliance of the patients.
Fourth, compared with the previous study asking the effi-
cacy of 4 mg trandolapril in chronic renal disease [3], the
anti-proteinuric efficacy obtained in the COOPERATE
was not less. Lastly, according to the official reports
of pharmacokinetic and pharmacodynamic variables of
trandolapril in Japanese patients with renal dysfunction
[4], these variables after 7 days’ consecutive use of even
1 mg are three times greater than those of patients with
congestive heart failure who have been treated with 4 mg
trandolapril.
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Reply from the Author
We appreciate the important additional information
from the COOPERATE trial [1] in the letter by Dr. Na-
kao regarding the dose of trandolapril used. We recognize
that 3 mg of trandolapril seems to be the optimal dose in
this Japanese population with nondiabetic renal disease.
This further supports the findings of an additional reno-
protective effect of treatment with both ACE inhibitors
(ACE-I) and angiotensin II receptor antagonists (ARB)
in patients with renal disease found in our own study of
diabetic nephropathy [2], as well as in the COOPERATE
trial [1]. However, it should be mentioned that the maxi-
mal recommended dose of trandolapril is 4 mg daily in
Europe and various renal diseases and ethnic groups [3]
have different degrees of renal and systemic activation of
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Fig. 1. (A) Homocysteine and (B) vascular en-
dothelial growth factor 2 (VEGFR-2) serum lev-
els in control, hemodialyzed (HD), and kidney
transplanted (KTx) patients. *P 0.05 vs. KTx
patients; **P  0.001 vs. KTx and control pa-
tients; #P  0.001 vs. KTx patients and P 
0.014 vs. control patients.
the renin-angiotensin system. Therefore, specific dosage
of ACE-I and ARBs may be required to obtain maximal
renoprotective effects in various populations. Unfortu-
nately, the optimal dosage of ACE-I has only been investi-
gated in Japanese patients with nonrenal disease [1].
Peter Jacobsen and Hans-Henrik Parving
Gentofte, Denmark
Correspondence to Peter Jacobsen, Steno Diabetes Center, Niels Steen-
sens Vej 2, 2820 Gentofte, Denmark.
E-mail: pkjacobsen@dadlnet.dk
REFERENCES
1. Nakao N, Yoshimura A, Morita H, et al: Combination treatment of
angiotensin-II receptor blocker and angiotensin-converting-enzyme
inhibitor in non-diabetic renal disease (COOPERATE): A random-
ised controlled trial. Lancet 361:117–124, 2003
2. Jacobsen P, Andersen S, Rossing K, et al: Dual blockade of the
renin-angiotensin system versus maximal recommended dose of
ACE inhibition in diabetic nephropathy. Kidney Int 63:1874–1880,
2003
3. Exner DV, Dries DL, Domanski MJ, Cohn JN: Lesser response
to angiotensin-converting-enzyme inhibitor therapy in black as com-
pared with white patients with left ventricular dysfunction. N Engl
J Med 344:1351–1357, 2001
Inverse association between
homocysteine and vascular
endothelial growth factor
receptor 2 serum levels in
hemodialyzed and kidney
transplanted patients
To the Editor: Homocysteine has an inhibitory effect
on angiogenesis [1]. However, the vascular endothelial
growth factor receptor-2 (VEGFR-2) gene has recently
been found up-regulated on human atherosclerotic plaques
[2]. In order to analyze the association between homocys-
teine and VEGFR-2 serum levels, we have randomly
selected 26 regular hemodialysis (HD) patients ages 56
12 years (mean  SD; M  14, F  12), and 26 age-
matched kidney transplanted individuals (KTx), ages
52  8 years (M  21, F  5). KTx transplant age was
13 9 months and creatinine was 1.6 0.5 mg/dL. Nine
age-matched healthy volunteers (47 5 years) were also
recruited. HD samples were collected at the end of the
long interval period. Serum homocysteine (Hcy) and
VEGFR-2 were tested by high-performance liquid chro-
matography (HPLC) with fluorimetric detection and a
commercial enzyme-linked immunosorbent assay (ELISA)
kit, respectively. Hcy was higher in HD patients (57 
36 mol/L) than in KTx patients (23  8 mol/L; P 
0.001) and control patients (15  6 mol/L; P  0.01
vs. HD; P  0.05 vs. KTx). VEGFR-2 was lower in HD
patients (1705 387 pg/mL) than in KTx patients (2449
825 pg/mL; P  0.014) or control patients (2150  464
pg/mL) (Fig. 1). The present study shows that Hcy and
circulating VEGFR-2 are inversely associated, consistent
with previous reports showing that homocysteine inhibits
angiogenesis. Our data also suggest that up-regulation
of the VEGFR-2 gene is probably a local finding, and that
hyperhomocysteinemia may be involved in the release of
VEGFR-2 into the systemic circulation.
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